Yuko Oya
Overview
Explore the profile of Yuko Oya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, et al.
Sci Rep
. 2023 Mar;
13(1):3698.
PMID: 36878936
Studies elucidating detailed characteristics of pneumonitis in association with chemo-immunotherapy are limited. We aimed to investigate the characteristics of images, prognostic factors, and clinical course of combination therapy associated with...
12.
Oya Y
Gan To Kagaku Ryoho
. 2023 Feb;
50(2):135-139.
PMID: 36807157
It has been more than 20 years since the first guidelines(GL)for cancer treatment were published, and the methodology used to create GL have changed over the years. The methodologies are...
13.
Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, et al.
Eur J Cancer
. 2022 Dec;
179:15-24.
PMID: 36470023
Introduction: Although osimertinib is a standard first-line treatment for patients with advanced-stage non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, the incidence rate of pneumonitis associated...
14.
Shimomura K, Yamaguchi T, Oya Y, Uchida K, Murotani K
Anticancer Res
. 2022 Dec;
42(12):5961-5969.
PMID: 36456164
Background/aim: The impact of corticosteroids for the treatment of immune-related adverse events (irAEs) on the antitumor effect of programmed cell death-1 (PD-1) inhibitor is unclear. Patients And Methods: A total...
15.
Masago K, Kuroda H, Takahashi Y, Oya Y, Sasaki E, Sakakura N, et al.
Cancer Genet
. 2022 Nov;
268-269:124-127.
PMID: 36332423
Concurrent EGFR mutation and ROS1 rearrangement is a rare event in early-stage non-small-cell lung cancer. In addition, a co-occurring de novo EGFR T790M mutation in such a case is extremely...
16.
Takeda Y, Kusaba Y, Tsukita Y, Uemura Y, Miyauchi E, Yamamoto T, et al.
Clin Transl Radiat Oncol
. 2022 Sep;
37:57-63.
PMID: 36065360
Purpose: Intensity-modulated radiotherapy (IMRT) is currently used more commonly than 3-dimensional conformal radiation for definitive thoracic radiation. We examined the efficacy profiles of concurrent chemoradiotherapy (CCRT) with IMRT after durvalumab...
17.
Kawachi H, Tamiya M, Taniguchi Y, Yokoyama T, Yokoe S, Oya Y, et al.
JTO Clin Res Rep
. 2022 Jun;
3(7):100355.
PMID: 35769388
Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard...
18.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, et al.
Chest
. 2022 Jun;
162(5):1188-1198.
PMID: 35661746
Background: Osimertinib has demonstrated impressive efficacy as a first-line treatment for patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung cancer. Drug-related pneumonitis (DRP) is a potentially lethal...
19.
Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Haratani K, et al.
JTO Clin Res Rep
. 2022 Feb;
3(2):100265.
PMID: 35146460
Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or...
20.
Sakakura N, Nakai A, Suda H, Nakada T, Matsui T, Nakanishi K, et al.
Mediastinum
. 2022 Feb;
5:19.
PMID: 35118325
This report presents an unusual case of life-threatening massive bleeding in the pulmonary trunk adjacent to the right ventricular outflow tract during resection of a large primary mediastinal nonseminomatous germ...